Secondary endpoints in the MINDFuL trial include the CDR-SB, E-Cog, ADL and Neuropsychiatric Inventory (NPI) instruments, along with blood biomarker and neuroimaging outcomes. Baseline demographics, ...
A study conducted by Prof. Thai-Yen Ling at National Taiwan University underscores the potential of small extracellular ...
Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK, March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback